<p>有些股票最好避免。当我们看到其他投资者遭受损失时，心里总是很难受。想想那些整整持有了 <strong>Standard BioTools Inc.</strong> (NASDAQ:LAB) 五年的人——他们的股价暴跌了 80%。我们还注意到，这只股票在过去一年表现不佳，股价下跌了 29%。此外，过去一周股价下跌了 15%。</p>
<p>由于 Standard BioTools 在过去 7 天内损失了 8500 万美元的市值，让我们看看长期的下滑是否是由公司经济状况驱动的。</p>
<p>我们发现 21 只美国股票预计明年将支付超过 6% 的股息收益率。查看完整列表，免费获取。</p>
<p>Standard BioTools 在过去十二个月内没有盈利，因此我们不太可能看到其股价与每股收益（EPS）之间有强相关性。可以说，收入是我们下一个最佳选择。当一家公司没有盈利时，我们通常希望看到良好的收入增长。可以想象，快速的收入增长在维持时，往往会导致快速的利润增长。</p>
<p>在五年内，Standard BioTools 的收入年均增长率为 2.6%。考虑到它正在亏损，这远非令人印象深刻。尽管如此，可以公平地说，快速下跌的股价（五年内复合下跌 12%）表明市场对这种增长水平非常失望。虽然我们对这只股票确实保持警惕，但在经历了这样的表现后，这可能是一种过度反应。像这样的公司通常需要在获得新投资者的青睐之前产生利润。</p>
<p>下图展示了收益和收入随时间的变化（点击图片可揭示确切数值）。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/742365-earnings-and-revenue-growth-1-dark-2/1767199144240?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/742365-earnings-and-revenue-growth-1-dark-2/1767199144240"/></p>
<p>NasdaqGS:LAB 收益和收入增长截至 2025 年 12 月 31 日</p>
<p>您可以在这个 <strong>免费</strong> 的互动图形中看到其资产负债表随时间的增强（或削弱）。</p>
<h2>不同的视角</h2>
<p>Standard BioTools 的股东今年下跌了 29%，而市场本身上涨了 18%。即使是优秀股票的股价有时也会下跌，但我们希望在过于关注之前，看到公司基本指标的改善。不幸的是，去年的表现可能表明未解决的挑战，因为它比过去五年年化损失 12% 的表现更糟糕。我们意识到巴伦·罗斯柴尔德曾说过投资者应该在 “街上有血时买入”，但我们提醒投资者首先要确保他们购买的是高质量的企业。虽然考虑市场条件对股价的不同影响是非常值得的，但还有其他更重要的因素。比如，投资风险的无处不在的阴影。<strong>我们发现了 Standard BioTools 的一个警告信号</strong>，理解这些信号应该是您投资过程的一部分。</p>
<p>但请注意：<strong>Standard BioTools 可能不是最佳买入股票</strong>。因此，请查看这个 <strong>免费</strong> 的有趣公司列表，这些公司过去有盈利增长（并且预计将进一步增长）。</p>
<p><em>请注意，本文中引用的市场回报反映了目前在美国交易所上市股票的市场加权平均回报。</em></p>
<p>移动基础设施用于国防和灾难</p>
<p>下一波机器人技术不是类人型的。它是完全自主的塔，在 30 分钟内提供 5G、ISR 和雷达，随时随地。</p>
<p>在下一轮合同之前获取投资者简报</p>
<p>由 CiTech 赞助</p>

<p>Standard BioTools（纳斯达克代码：LAB）经历了显著的下滑，本周股价下跌了 15%，过去五年内下跌了 80%。该公司报告称，过去一年股价下降了 29%，在过去十二个月内未实现盈利。年收入增长仅为 2.6%，导致市场失望。尽管整体市场上涨了 18%，Standard BioTools 的股东却面临损失，这引发了对公司未来表现和投资风险的担忧</p>

<p>Some stocks are best avoided. It hits us in the gut when we see fellow investors suffer a loss. Spare a thought for those who held <strong>Standard BioTools Inc.</strong> (NASDAQ:LAB) for five whole years - as the share price tanked 80%. We also note that the stock has performed poorly over the last year, with the share price down 29%. On top of that, the share price is down 15% in the last week.</p>
<div class="lb-trans"><p>有些股票最好避免。当我们看到其他投资者遭受损失时，心里总是很难受。想想那些整整持有了 <strong>Standard BioTools Inc.</strong> (NASDAQ:LAB) 五年的人——他们的股价暴跌了 80%。我们还注意到，这只股票在过去一年表现不佳，股价下跌了 29%。此外，过去一周股价下跌了 15%。</p>
</div><p>Since Standard BioTools has shed US$85m from its value in the past 7 days, let's see if the longer term decline has been driven by the business' economics.</p>
<div class="lb-trans"><p>由于 Standard BioTools 在过去 7 天内损失了 8500 万美元的市值，让我们看看长期的下滑是否是由公司经济状况驱动的。</p>
</div><p>We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.</p>
<div class="lb-trans"><p>我们发现 21 只美国股票预计明年将支付超过 6% 的股息收益率。查看完整列表，免费获取。</p>
</div><p>Standard BioTools wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). Arguably revenue is our next best option. When a company doesn't make profits, we'd generally hope to see good revenue growth. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.</p>
<div class="lb-trans"><p>Standard BioTools 在过去十二个月内没有盈利，因此我们不太可能看到其股价与每股收益（EPS）之间有强相关性。可以说，收入是我们下一个最佳选择。当一家公司没有盈利时，我们通常希望看到良好的收入增长。可以想象，快速的收入增长在维持时，往往会导致快速的利润增长。</p>
</div><p>Over five years, Standard BioTools grew its revenue at 2.6% per year. That's far from impressive given all the money it is losing. Nonetheless, it's fair to say the rapidly declining share price (down 12%, compound, over five years) suggests the market is very disappointed with this level of growth. While we're definitely wary of the stock, after that kind of performance, it could be an over-reaction. A company like this generally needs to produce profits before it can find favour with new investors.</p>
<div class="lb-trans"><p>在五年内，Standard BioTools 的收入年均增长率为 2.6%。考虑到它正在亏损，这远非令人印象深刻。尽管如此，可以公平地说，快速下跌的股价（五年内复合下跌 12%）表明市场对这种增长水平非常失望。虽然我们对这只股票确实保持警惕，但在经历了这样的表现后，这可能是一种过度反应。像这样的公司通常需要在获得新投资者的青睐之前产生利润。</p>
</div><p>The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image).</p>
<div class="lb-trans"><p>下图展示了收益和收入随时间的变化（点击图片可揭示确切数值）。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/742365-earnings-and-revenue-growth-1-dark-2/1767199144240" alt="" original-src="https://images.simplywall.st/asset/chart/742365-earnings-and-revenue-growth-1-dark-2/1767199144240"/></p>
<p>NasdaqGS:LAB Earnings and Revenue Growth December 31st 2025</p>
<div class="lb-trans"><p>NasdaqGS:LAB 收益和收入增长截至 2025 年 12 月 31 日</p>
</div><p>You can see how its balance sheet has strengthened (or weakened) over time in this <strong>free</strong> interactive graphic.</p>
<div class="lb-trans"><p>您可以在这个 <strong>免费</strong> 的互动图形中看到其资产负债表随时间的增强（或削弱）。</p>
</div><h2>A Different Perspective</h2>
<div class="lb-trans"><h2>不同的视角</h2>
</div><p>Standard BioTools shareholders are down 29% for the year, but the market itself is up 18%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. Unfortunately, last year's performance may indicate unresolved challenges, given that it was worse than the annualised loss of 12% over the last half decade. We realise that Baron Rothschild has said investors should &#34;buy when there is blood on the streets&#34;, but we caution that investors should first be sure they are buying a high quality business. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Consider for instance, the ever-present spectre of investment risk. <strong>We've identified 1 warning sign</strong> with Standard BioTools , and understanding them should be part of your investment process.</p>
<div class="lb-trans"><p>Standard BioTools 的股东今年下跌了 29%，而市场本身上涨了 18%。即使是优秀股票的股价有时也会下跌，但我们希望在过于关注之前，看到公司基本指标的改善。不幸的是，去年的表现可能表明未解决的挑战，因为它比过去五年年化损失 12% 的表现更糟糕。我们意识到巴伦·罗斯柴尔德曾说过投资者应该在 “街上有血时买入”，但我们提醒投资者首先要确保他们购买的是高质量的企业。虽然考虑市场条件对股价的不同影响是非常值得的，但还有其他更重要的因素。比如，投资风险的无处不在的阴影。<strong>我们发现了 Standard BioTools 的一个警告信号</strong>，理解这些信号应该是您投资过程的一部分。</p>
</div><p>But note: <strong>Standard BioTools may not be the best stock to buy</strong>. So take a peek at this <strong>free</strong> list of interesting companies with past earnings growth (and further growth forecast).</p>
<div class="lb-trans"><p>但请注意：<strong>Standard BioTools 可能不是最佳买入股票</strong>。因此，请查看这个 <strong>免费</strong> 的有趣公司列表，这些公司过去有盈利增长（并且预计将进一步增长）。</p>
</div><p><em>Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.</em></p>
<div class="lb-trans"><p><em>请注意，本文中引用的市场回报反映了目前在美国交易所上市股票的市场加权平均回报。</em></p>
</div><p>Mobile Infrastructure for Defense and Disaster</p>
<div class="lb-trans"><p>移动基础设施用于国防和灾难</p>
</div><p>The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.</p>
<div class="lb-trans"><p>下一波机器人技术不是类人型的。它是完全自主的塔，在 30 分钟内提供 5G、ISR 和雷达，随时随地。</p>
</div><p>Get the investor briefing before the next round of contracts</p>
<div class="lb-trans"><p>在下一轮合同之前获取投资者简报</p>
</div><p>Sponsored On Behalf of CiTech</p>
<div class="lb-trans"><p>由 CiTech 赞助</p>
</div>

Standard BioTools（NASDAQ:LAB）本周进一步疲软，下跌 15%，使五年累计损失达到 80%